Study guide

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia

Key Takeaways Explain This Topic AI

In pituitary apoplexy, intravenous hydrocortisone is given before any imaging or endocrine work-up because adrenal crisis is the immediate threat to life.

Dopamine antagonists such as antipsychotics, metoclopramide and domperidone are common causes of hyperprolactinaemia, typically below 2000 mU/L.

Macroprolactinomas are treated first line with a dopamine agonist such as cabergoline rather than surgery, even when there is visual field loss.

Last updated: September 2026

The pituitary gland (hypophysis) sits within the sella turcica of the sphenoid bone, immediately inferior to the optic chiasm. Mastery of the hypothalamic-pituitary-end organ axes, dynamic endocrine testing, hormonal hypersecretion syndromes, and water balance disorders is vital for MRCP(UK) Part 1.

  • 1. Hypopituitarism & Pituitary Apoplexy
  • Functional Anatomy & Vascular Supply

The pituitary comprises two embryologically distinct lobes:

Anterior Pituitary (Adenohypophysis): Derived from oral ectoderm (Rathke's pouch). Lacks a direct arterial blood supply; instead, hypothalamic releasing and inhibiting hormones are delivered via the hypothalamic-hypophyseal portal venous system originating from the superior hypophyseal artery.

Posterior Pituitary (Neurohypophysis): Derived from neural ectoderm. Receives direct arterial blood from the inferior hypophyseal arteries. Stores and secretes oxytocin and arginine vasopressin (AVP/ADH), which are synthesized in the paraventricular and supraoptic hypothalamic nuclei and transported down unmyelinated axons.

Etiologies of Hypopituitarism

Hypopituitarism denotes deficiency of one or more pituitary hormones. Primary pituitary causes must be distinguished from hypothalamic lesions:

Non-Functioning Pituitary Adenomas (~50%): Macroadenomas ( ≥ 10 mm \ge 10\text{ mm} ≥ 10 mm ) compress normal functional pituitary tissue and compromise portal blood flow.

Pituitary Surgery and Radiotherapy: Radiation-induced hypopituitarism develops insidiously over 2 to 10 years.

Sheehan's Syndrome (Postpartum Pituitary Necrosis): During pregnancy, the anterior pituitary undergoes physiological lactotroph hyperplasia without a corresponding increase in blood supply. Catastrophic obstetric haemorrhage and profound hypovolaemic shock lead to arterial vasospasm, ischaemic infarction, and necrosis of the anterior gland. Classically presents postpartum with failure of lactation (agalactorrhoea) , failure of menses resumption, profound lethargy, and secondary adrenal insufficiency.

Pituitary Apoplexy: Acute haemorrhage or infarction into a pre-existing (often undiagnosed) pituitary macroadenoma. Precipitating triggers include major surgery, cardiac bypass, dynamic pituitary function testing, and anticoagulation. Clinical triad: sudden-onset severe 'thunderclap' headache , visual disturbances ( bitemporal hemianopia or visual loss), and cranial nerve palsies (CN III, IV, VI) due to lateral expansion into the cavernous sinus. Acute secondary hypocortisolemia precipitates life-threatening cardiovascular collapse. Immediate management: Urgent blood draw for baseline endocrine profile, followed immediately by intravenous hydrocortisone (100 mg bolus) , fluid resuscitation, and emergency neurosurgical decompression if visual acuity or consciousness is compromised.

Lymphocytic Hypophysitis: Autoimmune lymphocytic infiltration of the pituitary gland and stalk, classically occurring in women during late pregnancy or the immediate postpartum period. MRI shows symmetric enlargement of the gland with homogeneous gadolinium enhancement and thickened pituitary stalk.

Craniopharyngioma: Benign, dysontogenetic suprasellar tumors arising from remnants of Rathke's pouch. Exhibits a bimodal age incidence (peaks at 5–14 years and 50–75 years). Histologically composed of squamous epithelium and cystic spaces filled with cholesterol-rich 'machinery oil' fluid; typically demonstrates suprasellar calcification on skull radiography or CT (present in > 80 % > 80\% > 80% of children and > 50 % > 50\% > 50% of adults). Compresses the optic chiasm (inferior bitemporal quadrantanopia progressing to bitemporal hemianopia) and hypothalamic-pituitary stalk, frequently provoking central diabetes insipidus and hypopituitarism.

Order of Anterior Pituitary Hormonal Loss

In progressive compressive or infiltrative lesions, anterior pituitary hormone secretion fails in a characteristic, highly reproducible sequence: GH ⟶ LH / FSH ⟶ TSH ⟶ ACTH \text{GH} \longrightarrow \text{LH / FSH} \longrightarrow \text{TSH} \longrightarrow \text{ACTH} GH ⟶ LH / FSH ⟶ TSH ⟶ ACTH

Growth Hormone (GH): First to decline. In adults, manifests as decreased lean muscle mass, central adiposity, reduced bone density, and impaired psychological quality of life.

Gonadotropins (LH / FSH): Causes hypogonadotrophic hypogonadism (oligomenorrhoea/amenorrhoea and vaginal dryness in premenopausal women; loss of libido, erectile dysfunction, and testicular atrophy in men).

TSH: Secondary (central) hypothyroidism with fatigue, cold intolerance, and weight gain. Serum free T4 is low, but serum TSH is inappropriately normal or low.

ACTH: Last to decline. Causes secondary adrenal insufficiency. Because the renin-angiotensin-aldosterone axis is regulated by renal perfusion and serum potassium, aldosterone secretion is entirely preserved . Thus, patients do not suffer hyperkalaemia, and hyperpigmentation is absent because ACTH and POMC are low.

MRCP Rule: Hormone Replacement Order: When initiating hormone replacement in panhypopituitarism, hydrocortisone must ALWAYS precede levothyroxine . Administering levothyroxine alone accelerates the hepatic clearance of endogenous cortisol, precipitating an acute, fatal Addisonian crisis.

Dynamic Endocrine Tests

Insulin Tolerance Test (ITT): The international gold standard for assessing both the hypothalamic-pituitary-adrenal (HPA) axis and GH reserve simultaneously. Intravenous soluble insulin ( 0.10 – 0.15 U/kg 0.10\text{–}0.15\text{ U/kg} 0.10 – 0.15 U/kg ) is administered to induce profound symptomatic hypoglycaemia (blood glucose < 2.2 mmol/L < 2.2\text{ mmol/L} < 2.2 mmol/L ). Adequate stress responses require a peak serum cortisol > 450 – 500 nmol/L > 450\text{–}500\text{ nmol/L} > 450 – 500 nmol/L and peak GH > 5 – 7 mcg/L > 5\text{–}7\text{ mcg/L} > 5 – 7 mcg/L ( > 15 – 20 mU/L > 15\text{–}20\text{ mU/L} > 15 – 20 mU/L ). Absolute contraindications: Ischaemic heart disease, epilepsy, severe cerebrovascular disease, and frail elderly patients.

Short Synacthen Test (SST): 250 mcg 250\text{ mcg} 250 mcg tetracosactide (synthetic ACTH 1–24) IM or IV. Measures adrenal cortisol output at 0 and 30 minutes (normal peak > 450 – 500 nmol/L > 450\text{–}500\text{ nmol/L} > 450 – 500 nmol/L ). Note: SST may be falsely normal in acute pituitary injury ( < 2 – 4 weeks < 2\text{–}4\text{ weeks} < 2 – 4 weeks ) because the adrenal cortex has not yet had sufficient time to undergo secondary atrophy.

  • 2. Hyperprolactinaemia & Prolactinomas
  • Physiological Regulation

Prolactin is unique among anterior pituitary hormones: its primary hypothalamic control is tonic inhibition mediated by dopamine acting on dopamine D2 receptors located on lactotroph cells. TRH, vasoactive intestinal peptide (VIP), and oestrogens act as physiological secretagogues.

Differential Diagnosis of Hyperprolactinaemia

Evaluating hyperprolactinaemia requires correlating serum prolactin concentrations with the clinical context:

Physiological: Pregnancy ( > 5000 mU/L > 5000\text{ mU/L} > 5000 mU/L ), lactation, intense physical exercise, severe systemic stress, venepuncture stress.

Pharmacological (Dopamine Antagonists): By far the most common non-physiological cause. Levels usually range between 1000 and 4000 mU/L 1000\text{ and }4000\text{ mU/L} 1000 and 4000 mU/L :

Antipsychotics: Typical neuroleptics (haloperidol, chlorpromazine) and atypical agents (especially risperidone and amisulpride).

Antiemetics / Prokinetics: Metoclopramide, domperidone.

Antidepressants: SSRIs, SNRIs, tricyclic antidepressants, and MAOIs.

Antihypertensives: Methyldopa, verapamil.

Opioids and H2-receptor antagonists.

Stalk Disconnection Effect: Any suprasellar mass, non-functioning pituitary macroadenoma, or infundibular infiltration (e.g. sarcoidosis, histiocytosis) compressing the pituitary stalk disrupts the transport of inhibitory dopamine from the hypothalamus to the adenohypophysis. Prolactin levels are mildly to moderately elevated, almost universally < 2000 mU/L < 2000\text{ mU/L} < 2000 mU/L (rarely up to 3000 mU/L 3000\text{ mU/L} 3000 mU/L ).

Prolactinomas (Lactotroph Adenomas):

Microprolactinoma ( < 10 mm < 10\text{ mm} < 10 mm ): Prolactin levels typically 2000 – 5000 mU/L 2000\text{–}5000\text{ mU/L} 2000 – 5000 mU/L . Far more common in premenopausal women (presenting early with oligomenorrhoea and galactorrhoea).

Macroprolactinoma ( ≥ 10 mm \ge 10\text{ mm} ≥ 10 mm ): Prolactin levels correlate with tumor volume and are characteristically > 5000 mU/L > 5000\text{ mU/L} > 5000 mU/L , frequently exceeding 10 , 000 – 20 , 000 mU/L 10,000\text{–}20,000\text{ mU/L} 10 , 000 – 20 , 000 mU/L . More common in men, presenting late with mass effects (headache, bitemporal upper quadrantanopia/hemianopia, hypopituitarism).

Systemic Conditions:

Primary Hypothyroidism: Elevated hypothalamic TRH stimulates lactotroph TRH receptors, causing mild hyperprolactinaemia ( 1000 – 2500 mU/L 1000\text{–}2500\text{ mU/L} 1000 – 2500 mU/L ). Always measure serum TSH before performing pituitary MRI!

Chronic Kidney Disease: Impaired renal clearance of prolactin.

Macroprolactinaemia: Biologically inactive complexes of monomeric prolactin with IgG autoantibodies. Detected via polyethylene glycol (PEG) precipitation ; prevents unnecessary neuroimaging or dopamine agonist therapy.

'Hook Effect': In massive macroprolactinomas with prolactin > 50 , 000 mU/L > 50,000\text{ mU/L} > 50 , 000 mU/L , antigen excess saturates both capture and detection antibodies in two-site immunometric assays, yielding a falsely low reading (e.g. 1000 mU/L 1000\text{ mU/L} 1000 mU/L ). Performing serial serum dilutions unmasks the true astronomical concentration.

Clinical Features & Medical Management

Clinical features include galactorrhoea (milky breast secretion), secondary amenorrhoea/oligomenorrhoea, subfertility, and accelerated osteopenia/osteoporosis secondary to hypogonadotrophic hypogonadism. In men, manifestations include decreased libido, erectile dysfunction, gynaecomastia, and visual loss.

First-Line Therapy: Medical management with oral dopamine D2 receptor agonists is first-line for both micro- and macroprolactinomas:

Cabergoline: Preferred agent of choice. Administered once or twice weekly. Significantly superior to bromocriptine in achieving prolactin normalisation ( > 85 % > 85\% > 85% ) and tumor shrinkage ( > 80 % > 80\% > 80% ), with superior gastrointestinal tolerability. Potential adverse effects include nausea, orthostatic hypotension, impulse control disorders (pathological gambling, hypersexuality), and psychiatric symptoms. At the high doses used in Parkinson's disease, cabergoline is associated with 5-HT2B receptor-mediated cardiac valvulopathy; baseline echocardiography is standard practice.

Bromocriptine: Short-acting daily oral agent; alternative if pregnancy is actively planned, though cabergoline safety in pregnancy is well established.

Surgical Indications: Transsphenoidal hypophysectomy is reserved for dopamine agonist resistance, intractable drug intolerance, or acute apoplexy with progressive visual deterioration.